Melatonin and Antidepressants: Documented Interactions
Melatonin is the most widely used sleep support supplement in the world, and sleep difficulties are commonly reported alongside other conditions. That means many people are combining melatonin with an antidepressant every night, often without a second thought. Studies have not documented a pharmacokinetic interaction with most SSRIs/SNRIs; additive drowsiness is possible, and fluvoxamine is a documented exception. In one study, fluvoxamine raised total melatonin exposure about 17-fold. This guide walks through the major antidepressant classes and the other documented cautions.
Key Takeaways
- ✓Studies have not documented a pharmacokinetic interaction with most SSRIs/SNRIs; additive drowsiness is possible, and fluvoxamine is a documented exception.
- ✓Fluvoxamine is the major outlier. It inhibits CYP1A2, the enzyme that metabolizes melatonin; in a study it raised total melatonin exposure (AUC) about 17-fold and peak levels about 12-fold. Avoid melatonin with fluvoxamine unless the prescriber specifically advises it.
- ✓Combining melatonin with sedating antidepressants like trazodone or mirtazapine produces additive drowsiness that may impair next-day functioning.
- ✓Melatonin is prescription-only in the UK, and the EU health claim is for 1 mg taken close to bedtime. The 5–10 mg (and higher) products common in the US are far above this.
- ✓Other cautions: other CYP1A2 inhibitors (such as ciprofloxacin and oestrogen-containing contraceptives or HRT) also raise melatonin; INR changes with warfarin are listed in the prolonged-release melatonin product information; avoid alcohol and driving after taking it; use in pregnancy or breastfeeding is not recommended.
- ✓Agomelatine is a prescription antidepressant that works directly on melatonin receptors. Combining it with supplemental melatonin is generally considered contraindicated.
1. How Melatonin Works Beyond Sleep
Most people think of melatonin as a simple sleep hormone, but there is much more going on. This is worth understanding. Produced by the pineal gland (a tiny structure deep in the brain) in response to darkness, melatonin acts on two primary receptor subtypes, MT1 and MT2, distributed throughout the brain, cardiovascular system, immune cells, and gastrointestinal tract.
MT1 receptor activation promotes sleepiness by quieting neurons in the suprachiasmatic nucleus (SCN), the body's master circadian clock. MT2 receptor activation is what actually shifts circadian phase. In plain terms, that is the mechanism responsible for resetting the internal clock when melatonin is taken at a strategic time.
Beyond sleep, laboratory studies describe melatonin as an antioxidant, a modulator of immune function, and an influence on neurotransmitter systems that overlap directly with antidepressant pharmacology:
- Serotonin precursor relationship. Melatonin is synthesized from serotonin. The pathway runs tryptophan → serotonin → N-acetylserotonin → melatonin. This means melatonin and serotonin levels are biochemically linked, and alterations in one system can influence the other.
- GABAergic enhancement. Melatonin potentiates GABA-A (related to GABA, a calming brain chemical) receptor activity at physiological concentrations, contributing to its sedative effects and creating additive potential with other GABAergic agents.
- Anti-inflammatory action. Melatonin suppresses NF-kB signaling and reduces pro-inflammatory cytokines, which is relevant given the neuroinflammatory hypothesis of depression.
- CYP1A2 metabolism. Melatonin is primarily metabolized by the liver enzyme CYP1A2, with minor contributions from CYP2C19. Here's the key point: any drug that inhibits CYP1A2 will dramatically increase circulating melatonin. This is the single most important pharmacological fact in this entire guide.
2. Melatonin and SSRIs: One Major Exception
The selective serotonin reuptake inhibitors (SSRIs), including sertraline, escitalopram, fluoxetine, citalopram, paroxetine, and fluvoxamine, are the most commonly prescribed antidepressant class. For five of these six drugs, studies have not documented a pharmacokinetic interaction with melatonin. The sixth, fluvoxamine, is a different story entirely.
The General SSRI Picture
SSRIs increase serotonin availability in the synapse by blocking the serotonin transporter (SERT). Because melatonin is synthesized downstream from serotonin, there has been theoretical interest in whether SSRIs alter melatonin production. The clinical data is mixed: some studies show SSRIs like fluoxetine may slightly suppress nocturnal melatonin secretion, while others show no significant change.
Studies have not documented a pharmacokinetic interaction with most SSRIs/SNRIs; additive drowsiness is possible, and fluvoxamine is a documented exception. This applies to combinations such as melatonin and sertraline ormelatonin and escitalopram. Anyone taking an antidepressant should tell the prescriber about melatonin.
Fluvoxamine: The Critical Exception
Fluvoxamine, while technically an SSRI, has a unique pharmacological property that sets it apart: it is one of the most potent inhibitors of the CYP1A2 enzyme among all commonly prescribed medications. This matters enormously because CYP1A2 is the primary enzyme responsible for breaking down melatonin in the liver.
When fluvoxamine blocks CYP1A2, melatonin cannot be metabolized at its normal rate. The result is striking: in a pharmacokinetic (how the body processes the drug) study in healthy volunteers (Härtter et al., 2000), fluvoxamine raised total melatonin exposure (AUC, area under the curve) about 17-fold and peak levelsabout 12-fold.
The consequences of this interaction include:
- Profound next-day sedation. Patients report being unable to wake up, experiencing a “drugged” hangover quality, and showing significantly impaired psychomotor performance the following morning.
- Excessive drowsiness and vivid dreams. The amplified melatonin levels extend REM sleep and produce intensely vivid, sometimes disturbing dreams.
- Potential hypothermia. Melatonin at high concentrations lowers core body temperature, and supraphysiological levels can produce clinically significant hypothermic effects.
- Altered mood and cognition. Some patients experience paradoxical worsening of depressive symptoms due to excessive daytime sedation and circadian disruption.
What practitioners typically consider: Avoid melatonin with fluvoxamine unless the prescriber specifically advises it. The product information for prescription melatonin advises against combining it with fluvoxamine.
3. Melatonin and SNRIs
Serotonin-norepinephrine reuptake inhibitors (SNRIs), principally venlafaxine and duloxetine, have a similar documented interaction profile to most SSRIs when combined with melatonin. Neither venlafaxine nor duloxetine is a significant CYP1A2 inhibitor, which means they do not produce the dramatic pharmacokinetic interaction seen with fluvoxamine.
The primary consideration is additive effects on serotonin signaling. Because melatonin is synthesized from serotonin and can modestly influence serotonergic (affecting serotonin levels) tone, the theoretical concern of enhanced serotonergic activity exists. However, melatonin's effect on serotonin is far weaker than that of any prescription serotonergic agent, and no published case reports link melatonin-SNRI co-administration to serotonin syndrome.
Duloxetine, which is metabolized primarily by CYP1A2 and CYP2D6, has a minor bidirectional interaction: both duloxetine and melatonin compete for CYP1A2, which may modestly raise levels of both compounds. This effect is not clinically significant for most patients but is worth noting in individuals who are already slow CYP1A2 metabolizers (e.g., non-smokers on high-dose duloxetine).
What practitioners typically consider: Studies have not documented a pharmacokinetic interaction with most SSRIs/SNRIs; additive drowsiness is possible, and fluvoxamine is a documented exception. Many healthcare providers prefer to be informed about all supplements their patients are taking, particularly for those on duloxetine at doses above 60 mg daily.
4. Melatonin and Sedating Antidepressants
Two antidepressants frequently prescribed specifically for their sleep-promoting properties, trazodone and mirtazapine, deserve special attention because their mechanism of action overlaps functionally with melatonin's sedative effects.
Trazodone
Trazodone is an atypical antidepressant that, at the low doses commonly used for insomnia (25–100 mg), acts primarily as a serotonin 5-HT2A antagonist and histamine H1 blocker. This combination produces reliable sedation without the dependence risk of benzodiazepines or Z-drugs. Adding melatonin to trazodone creates a dual-sedation scenario: trazodone sedates through antihistaminic and serotonergic mechanisms while melatonin sedates through MT1 receptor activation and GABA potentiation.
Additive drowsiness is possible: the cumulative sedation can impair next-morning alertness, increase fall risk (particularly in older adults), and produce a groggy, “hungover” quality that undermines daytime functioning.
The important thing to know: several clinicians note that patients taking trazodone for sleep rarely need supplemental melatonin. If they do, it often suggests the trazodone dose needs adjustment rather than the addition of another sedating agent.
Mirtazapine
Mirtazapine is one of the most sedating antidepressants available, acting as a potent histamine H1 antagonist, 5-HT2A antagonist, and 5-HT2C antagonist. Its sedation is most pronounced at lower doses (7.5–15 mg), where antihistaminic activity predominates before noradrenergic effects emerge at higher doses.
Combining melatonin with mirtazapine amplifies the sedative burden similarly to trazodone. Additionally, mirtazapine commonly causes weight gain and increased appetite, and there is preliminary evidence that chronically elevated melatonin may influence glucose metabolism and insulin sensitivity, though this remains an area of active research.
What practitioners typically consider: For individuals taking trazodone or mirtazapine for sleep, adding melatonin is usually considered unnecessary in the clinical literature and may worsen next-day drowsiness. If insomnia persists despite these medications, some practitioners advise investigating the underlying cause rather than layering additional sedating supplements (such as ashwagandha or valerian). If the combination is used, it should be at the prescriber's direction.
5. Melatonin and Mood Stabilizers (Lithium)
Lithium occupies a unique position in psychopharmacology as both a mood stabilizer and an augmentation agent for treatment-resistant depression. Its relationship with melatonin is pharmacologically interesting: lithium has been shown to increase endogenous melatonin secretion by enhancing the activity of arylalkylamine N-acetyltransferase (AANAT), the rate-limiting enzyme in melatonin synthesis.
This means that patients on lithium may already have higher-than-normal nighttime melatonin levels. Adding supplemental melatonin on top of this endogenous increase can produce excessive total melatonin exposure, potentially causing oversedation, vivid dreams, and next-day cognitive dulling.
There is also a more nuanced concern: melatonin influences renal function and electrolyte handling, and lithium has a notoriously narrow therapeutic index with renal excretion. While no direct interaction has been established, anything that alters renal physiology in a patient on lithium warrants caution.
What practitioners typically consider: For individuals on lithium, some practitioners advise using melatonin only under medical supervision and at the lowest effective dose. It is commonly noted that lithium levels are monitored at their usual intervals, with clinicians aware that melatonin has been added to the regimen.
6. Dose and Product Strength
How melatonin is sold depends heavily on where you live, and this matters for interactions.
In the US, melatonin is sold as a dietary supplement, and you will find products of 5 mg, 10 mg, and even 20 mg. In the UK, melatonin is prescription-only. In the EU, the authorised health claim (melatonin contributes to the reduction of time taken to fall asleep) applies to 1 mg taken close to bedtime. The amount the pineal gland produces each night is far smaller than most US products.
This dosage issue becomes especially important in the context of antidepressant co-administration:
- Higher doses mean more overlap. Additive drowsiness with sedating medicines rises with the dose of melatonin.
- Fluvoxamine. Because fluvoxamine multiplies melatonin exposure, high-strength products are a particular concern. Avoid melatonin with fluvoxamine unless the prescriber specifically advises it.
- Morning grogginess compounds antidepressant fatigue. Many antidepressants cause daytime fatigue, especially during initiation. High-dose melatonin amplifies this problem and can be misattributed to the antidepressant rather than the supplement.
What practitioners typically consider: The EU health claim relates to 1 mg taken close to bedtime. For individuals taking any antidepressant, melatonin is best discussed with the prescriber first. Avoid melatonin with fluvoxamine unless the prescriber specifically advises it.
7. Timing Optimization
When melatonin is taken matters as much as how much is taken. Timing becomes more nuanced when antidepressants are part of the equation.
- For sleep onset: The literature typically recommends melatonin 30–60 minutes before the intended bedtime. Standard melatonin has a half-life of roughly 40–60 minutes, so taking it too early reduces its effectiveness at the moment of desired sleep onset.
- For circadian resetting: For individuals whose sleep schedule is delayed (falling asleep at 2 AM, waking at 10 AM), some practitioners advise a low dose (0.5 mg) approximately 4–5 hours before the desired bedtime to gradually advance the circadian phase.
- Morning or afternoon dosing considerations: Unlike many supplements, melatonin is generally considered inadvisable during the day. Daytime melatonin sends a confusing signal to the SCN, can worsen depressive symptoms by promoting sleepiness when alertness is needed, and may interfere with morning antidepressant efficacy.
8. When Melatonin Is the Wrong Choice
Melatonin is not appropriate for every type of insomnia, and this distinction is especially important for people with depression. Individuals may wish to reconsider melatonin if:
- The insomnia is maintenance-type, not onset-type. If falling asleep is easy but waking at 3 AM is the problem, standard melatonin is unlikely to help. This pattern, which is common in depression, is related to cortisol dysregulation (stress hormone imbalance) and hyperarousal rather than melatonin deficiency. Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia in clinical guidelines.
- You are taking fluvoxamine. Avoid melatonin with fluvoxamine unless the prescriber specifically advises it.
- You are already on two or more sedating medications. Adding melatonin to a regimen that includes a sedating antidepressant plus a benzodiazepine, gabapentin, or antihistamine creates excessive CNS depression risk.
- Your insomnia started with your antidepressant. SSRIs like fluoxetine and sertraline commonly cause insomnia in the first 2–4 weeks of treatment. This is usually transient and may resolve without intervention. Discuss timing adjustments (taking the SSRI in the morning rather than evening) before adding melatonin.
- You have an autoimmune condition. The product information for prescription melatonin advises against use in autoimmune disease, because there are no clinical data and melatonin may affect immune function.
- You are pregnant or breastfeeding. Use is not recommended because there are not enough data.
9. The Agomelatine Connection
No discussion of melatonin and antidepressants is complete without addressing agomelatine, a prescription antidepressant available in Europe and Australia (though not approved in the United States) that works directly on the melatonin system.
Agomelatine is a melatonin MT1/MT2 receptor agonist and a serotonin 5-HT2C antagonist. This dual mechanism makes it unique among antidepressants: it resynchronizes disrupted circadian rhythms through melatonergic activation while simultaneously enhancing norepinephrine and dopamine release in the prefrontal cortex through 5-HT2C blockade.
The clinical relevance is straightforward: supplemental melatonin alongside agomelatine is generally considered contraindicated. The combination would produce excessive MT1/MT2 receptor stimulation, potentially causing profound sedation, circadian disruption, and unpredictable mood effects. Agomelatine already provides melatonergic activity at pharmacologically optimized levels. Adding exogenous (supplemental) melatonin on top of that is both redundant and risky.
Agomelatine also carries a well-documented risk of hepatotoxicity (potential liver damage), requiring liver function monitoring at treatment initiation, after 3 weeks, 6 weeks, 12 weeks, and 24 weeks. While melatonin itself is not hepatotoxic, the CYP1A2 competition could theoretically alter agomelatine clearance, and any additional burden on hepatic metabolism in patients being monitored for liver injury is undesirable.
Some researchers have investigated whether melatonin supplements might have antidepressant effects of their own; the evidence is preliminary and inconsistent, and melatonin is not a treatment for depression.
10. Other Documented Interactions and Cautions
- Other CYP1A2 inhibitors. Fluvoxamine is the strongest, but other medicines that inhibit CYP1A2 also raise melatonin levels, including the antibiotic ciprofloxacin andoestrogen-containing contraceptives or HRT.
- Warfarin. Changes in INR are listed in the product information for prescription prolonged-release melatonin. People taking warfarin should tell their anticoagulation clinic before starting melatonin.
- Alcohol and driving. Alcohol should be avoided with melatonin, and melatonin can cause drowsiness: do not drive or operate machinery until you know how it affects you.
- Pregnancy and breastfeeding. Melatonin is not recommended during pregnancy or breastfeeding.
Summary: Quick Reference by Antidepressant
For quick reference, here is a practical summary of documented melatonin interactions across major antidepressant classes:
- Sertraline, escitalopram, citalopram, paroxetine, fluoxetine: No pharmacokinetic interaction documented. Additive drowsiness is possible.
- Fluvoxamine: Avoid melatonin with fluvoxamine unless the prescriber specifically advises it. In a study it raised melatonin exposure about 17-fold (AUC) and peak levels about 12-fold.
- Venlafaxine, duloxetine: No pharmacokinetic interaction documented; additive drowsiness is possible. Minor CYP1A2 competition with duloxetine.
- Trazodone, mirtazapine: Additive sedation risk. Usually unnecessary; if used, only at the prescriber's direction.
- Lithium: Caution. Lithium increases endogenous melatonin. Use lowest dose, monitor lithium levels.
- Agomelatine: Contraindicated. Agomelatine is itself a melatonin receptor agonist.
Does melatonin interact with antidepressants? Studies have not documented a pharmacokinetic interaction with most SSRIs/SNRIs; additive drowsiness is possible, and fluvoxamine is a documented exception. Many products sold in the US are far stronger than the 1 mg covered by the EU health claim. And if fluvoxamine is in the regimen, avoid melatonin unless the prescriber specifically advises it. Many healthcare providers prefer to be informed about all supplements their patients are taking: knowing the specific medication, using the lowest effective melatonin dose, and maintaining open communication with a healthcare provider are commonly cited best practices in the literature.
Sources & Further Reading
- Härtter S, et al. "Increased bioavailability of oral melatonin after fluvoxamine coadministration." Clin Pharmacol Ther. 2000;67(1):1-6. PMID 10668847.
- Prolonged-release melatonin 2 mg tablets. Summary of Product Characteristics (EU/UK).
- Commission Regulation (EU) No 432/2012: authorised health claim for melatonin (reduction of time taken to fall asleep; 1 mg close to bedtime).
- De Berardis D, et al. "Agomelatine beyond boundaries: current evidences." Riv Psichiatr. 2015;50(4):154-159.
- Natural Medicines Comprehensive Database. "Melatonin Monograph." Therapeutic Research Center.
This article synthesizes findings from peer-reviewed research, pharmacological databases, and clinical monographs. It is intended for educational purposes and does not constitute medical advice.
Check your specific combination
Enter your antidepressant and any supplements you're considering into our free Interaction Reference.
Open Interaction Reference